Skip to main content
HairCited

Minoxidil für Weiblicher Haarausfall

A

Basierend auf 67 Studien (4 meta-analyses, 11 RCTs) mit 28,815 Teilnehmern insgesamt. 53/67 Studien zeigen positive Effekte.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dminoxidil\u0026condition\u003Dfemale\u002Dpattern\u002Dhair\u002Dloss'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

Fazit

Research strongly suggests that minoxidil may help women with female pattern hair loss regain hair density, supported by numerous high-quality clinical trials.

  • 67 studies including 11 RCTs and 4 meta-analyses specifically in women
  • 79% of studies report positive effects on hair growth
  • Low-dose oral minoxidil is emerging as a well-tolerated alternative to topical application
  • Combination with other ingredients like spironolactone may enhance results

Key Study Findings

Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs.: None Outcome: None Wirkung: None None

Population: women with androgenetic alopecia (female pattern hair loss)

Other
Low-dose oral minoxidil (LDOM) and topical minoxidil: consensus recommendations for managing male and female pattern …
Dose: MPHL: 1.25-2.5 mg/day; FPHL: 0.625-1.25 mg/day vs.: None Outcome: consensus recommendations for managing pattern hair loss Wirkung: None None

Population: hair transplant patients with male and female pattern hair loss (Delphi panel consensus)

review
Antiandrogen therapy for the treatment of female pattern hair loss: A clinical review of current …
Dose: varies by agent and study vs.: Placebo Wirkung: variable; oral antiandrogens demonstrate some efficacy; topical antiandrogens possibly fewer systemi None
narrative review
Addressing the Root Causes of Female Hair Loss and Non-Pharmaceutical Interventions.
Dose: None vs.: Placebo Wirkung: None None
randomized controlled trial n=45 16 weeks Open-label
Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in …
Dose: Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi vs.: Placebo Wirkung: Groups A and C showed significant improvement on Sinclair scale and trichoscopic hair density; Group None
Review
Male and female pattern hair loss.
Dose: None vs.: Placebo Wirkung: None None

Key Statistics

111

Studien

37800

Teilnehmer

Positive

A

Bewertung

Referenced Papers

Australian prescriber 2025 2 Zitierungen
Annals of dermatology 2025
SAGE open medical … 2024 3 Zitierungen
Drugs 2023 221 Zitierungen
Anais brasileiros de … 2023 29 Zitierungen
Journal of cosmetic … 2023 3 Zitierungen
The Journal of … 2022 170 Zitierungen
Faculty reviews 2022 44 Zitierungen
Journal of cosmetic … 2022 7 Zitierungen
Journal of the … 2021 42 Zitierungen
American journal of … 2020 127 Zitierungen
International journal of … 2020 58 Zitierungen
Indian dermatology online … 2020 31 Zitierungen
Journal of drugs … 2019 20 Zitierungen
Actas dermo-sifiliograficas 2019 5 Zitierungen
International journal of … 2018 129 Zitierungen
Australian journal of … 2018 8 Zitierungen
JAMA dermatology 2017 121 Zitierungen
The Cochrane database … 2016 18 Zitierungen
The Medical clinics … 2015 66 Zitierungen
World journal of … 2015 62 Zitierungen
Seminars in cutaneous … 2015 20 Zitierungen
Clinical obstetrics and … 2015 9 Zitierungen
Current problems in … 2015 8 Zitierungen
Skin therapy letter 2014 29 Zitierungen
Journal of drugs … 2014 26 Zitierungen
Dermatologic clinics 2013 78 Zitierungen
International journal of … 2013 61 Zitierungen
Indian journal of … 2013 16 Zitierungen
International journal of … 2013
The Cochrane database … 2012 15 Zitierungen
Skinmed 2012 5 Zitierungen
The Australasian journal … 2011 44 Zitierungen
Seminars in cutaneous … 2009 4 Zitierungen
American family physician 2009
Journal of the … 2008 290 Zitierungen
The Australasian journal … 2007 32 Zitierungen
Clinical interventions in … 2007
Duodecim; laaketieteellinen aikakauskirja 2006
Journal of the … 2005 247 Zitierungen
The British journal … 2005 205 Zitierungen
The journal of … 2003 102 Zitierungen
Clinical and experimental … 2002 61 Zitierungen
Therapeutische Umschau. Revue … 2002 4 Zitierungen

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Übliche Dosierungen

topical:
2-5% solution, twice daily

Obergrenze: 5% topical solution

In der Forschung untersuchte Dosierungen

Dosierung Dauer Wirkung N
None -- Neutral --
MPHL: 1.25-2.5 mg/day; FPHL: 0.625-1.25 mg/day -- Positive --
varies by agent and study -- Positive --
None -- Positive --
Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi 16 weeks Positive 45
None -- Positive --
Spironolactone 100 mg once daily 24 weeks Positive 48
None -- Positive --

Beste Einnahmezeit: Apply to dry scalp morning and evening, at least 4 hours before bed

Safety & Side Effects

Gemeldete Nebenwirkungen

  • Scalp irritation and dryness
  • Initial shedding phase (first 2-8 weeks)
  • Unwanted facial hair growth (especially in women)
  • Dizziness or lightheadedness (rare with topical use)
  • Heart palpitations (rare, more common with oral form)

Bekannte Wechselwirkungen

  • Antihypertensive medications (additive blood pressure lowering)
  • Topical corticosteroids (may increase absorption)
  • Retinoids (tretinoin may enhance penetration and side effects)

Tolerierbare Höchstaufnahmemenge: 5% topical solution

Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.

Frequently Asked Questions

Does Minoxidil help with Weiblicher Haarausfall?
Based on 111 studies with 37,800 participants, there is strong evidence from multiple clinical trials that Minoxidil may support Weiblicher Haarausfall management. Our evidence grade is A (Strong Evidence).
How much Minoxidil should I take for Weiblicher Haarausfall?
Studies have used various dosages. A commonly studied range is 2-5% solution, twice daily. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Minoxidil?
Reported side effects may include Scalp irritation and dryness, Initial shedding phase (first 2-8 weeks), Unwanted facial hair growth (especially in women), Dizziness or lightheadedness (rare with topical use). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Minoxidil and Weiblicher Haarausfall?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 111 peer-reviewed studies with 37,800 total participants. The overall direction of effect is positive.

Related Evidence

FDA-Haftungsausschluss: Diese Aussagen wurden nicht von der Food and Drug Administration bewertet. Die Produkte und Informationen auf dieser Website sind nicht dazu bestimmt, Krankheiten zu diagnostizieren, zu behandeln, zu heilen oder zu verhindern. Die dargestellten Evidenzbewertungen basieren auf unserer Analyse veröffentlichter begutachteter Forschung und stellen keine medizinische Beratung dar. Konsultieren Sie immer Ihren Arzt, bevor Sie mit der Einnahme von Nahrungsergänzungsmitteln beginnen.